A Lactose-Selective α1,3-Fucosyltransferase from Akkermansia muciniphila Expands the Biosynthetic Toolkit for Fucosylated Human Milk Oligosaccharides
ACS Synthetic Biology · 2026
DOI: 10.1021/acssynbio.6c00427 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Synthetic Biology, 2026. Verfasst von Cheng-Huan Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsinchu300044, Taiwan. Hauptthemen laut MEDLINE: Milk, Human, Fucosyltransferases, Lactose, Oligosaccharides. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Tsing Hua University, National Science and Technology Council.
Abstract (Originalsprache)
Fucosylated human milk oligosaccharides (HMOs) are important bioactive glycans, but their biosynthetic production requires fucosyltransferases with predictable acceptor selectivity to avoid regioisomer formation and downstream purification burdens. Here we identify an α1,3-fucosyltransferase from Akkermansia muciniphila (AkkFT) that functions as a lactose-selective α1,3-fucosylation module for HMO synthesis. AkkFT preferentially acts on glycans containing a lactose unit and shows no detectable conversion of type-1 or type-2 N-acetyllactosamine acceptors under standard conditions, contrasting with commonly used bacterial α1,3/4-fucosyltransferases. This lactose-anchored selectivity enables late-stage α1,3-fucosylation across neutral and sialylated HMO acceptors, including efficient formation of lacto-N-neofucopentaose V and the blood group B antigen. Notably, AkkFT converts disialyl-lacto-N-tetraose to disialyl-lacto-N-fucopentaose V under conditions where Helicobacter pylori α1,3-fucosyltransferases show no detectable activity. AkkFT also converts free 2′-fucosyllactose to lactodifucotetraose on a preparative scale and was implemented in an engineered Escherichia coli strain for whole-cell 3-fucosyllactose production. Overall, AkkFT expands the repertoire of selectivity-defined biosynthetic parts for fucosylated HMO production and demonstrates how enzyme discovery can complement engineered microbial platforms for glycan biomanufacturing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, National Tsing Hua University, 101, Section 2, Kuang-Fu Road, Hsinchu300044, Taiwan.
- Department of Biotechnology and Food Technology, Southern Taiwan University of Science and Technology, 1, Nantai Street,Yungkang District, Tainan710301, Taiwan.
- Institute of Biological Chemistry, Academia Sinica, 128, Academia Road Sec. 2, Nankang, Taipei115201, Taiwan.
- Department of Medicinal and Applied Chemistry, Kaohsiung Medical University, 100, Shiquan first Road, Kaohsiung807378, Taiwan.
ORCID-Profile: Cheng-Huan Liu, Kai-Eng Ooi, Mei-Ting Lin, Guan-Chun Wu, Hsiang-En Chen, Po-Ting Chen, Ching-Ching Yu
Förderung
- National Tsing Hua University
- National Science and Technology Council
Zitieren
APA
Liu, C. H., Ooi, K. E., Lin, M. T., Cheng, Y. J., Wu, G. C., Hsieh, W. Y., Chen, H. E., Chen, P. T., & Yu, C. C. (2026). A Lactose-Selective α1,3-Fucosyltransferase from Akkermansia muciniphila Expands the Biosynthetic Toolkit for Fucosylated Human Milk Oligosaccharides. ACS Synthetic Biology. https://doi.org/10.1021/acssynbio.6c00427
Vancouver
Liu CH, Ooi KE, Lin MT, Cheng YJ, Wu GC, Hsieh WY, et al. A Lactose-Selective α1,3-Fucosyltransferase from Akkermansia muciniphila Expands the Biosynthetic Toolkit for Fucosylated Human Milk Oligosaccharides. ACS Synthetic Biology. 2026. doi:10.1021/acssynbio.6c00427
BibTeX
@article{Liu2026,
author = {Liu, Cheng-Huan and Ooi, Kai-Eng and Lin, Mei-Ting and Cheng, Yung-Jen and Wu, Guan-Chun and Hsieh, Wan-Yu and Chen, Hsiang-En and Chen, Po-Ting and Yu, Ching-Ching},
title = {A Lactose-Selective α1,3-Fucosyltransferase from Akkermansia muciniphila Expands the Biosynthetic Toolkit for Fucosylated Human Milk Oligosaccharides},
journal = {ACS Synthetic Biology},
year = {2026},
doi = {10.1021/acssynbio.6c00427}
}
EUVIMED